OBJECTIVE: To evaluate warfarin prescription, quality of international normalised ratio (INR) monitoring and of INR control in patients with atrial fibrillation (AF) and chronic kidney disease (CKD). METHODS: We performed a retrospective cohort study of patients with newly diagnosed AF in the Veterans Administration (VA) healthcare system. We evaluated anticoagulation prescription, INR monitoring intensity and time in and outside INR therapeutic range (TTR) stratified by CKD. RESULTS: Of 123 188 patients with newly diagnosed AF, use of warfarin decreased with increasing severity of CKD (57.2%-46.4%), although it was higher among patients on dialysis (62.3%). Although INR monitoring intensity was similar across CKD strata, the proportion with TTR≥60% decreased with CKD severity, with only 21% of patients on dialysis achieving TTR≥60%. After multivariate adjustment, the magnitude of TTR reduction increased with CKD severity. Patients on dialysis had the highest time markedly out of range with INR <1.5 or >3.5 (30%); 12% of INR time was >3.5, and low TTR persisted for up to 3 years. CONCLUSIONS: There is a wide variation in anticoagulation prescription based on CKD severity. Patients with moderate-to-severe CKD, including dialysis, have substantially reduced TTR, despite comparable INR monitoring intensity. These findings have implications for more intensive warfarin management strategies in CKD or alternative therapies such as direct oral anticoagulants. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
OBJECTIVE: To evaluate warfarin prescription, quality of international normalised ratio (INR) monitoring and of INR control in patients with atrial fibrillation (AF) and chronic kidney disease (CKD). METHODS: We performed a retrospective cohort study of patients with newly diagnosed AF in the Veterans Administration (VA) healthcare system. We evaluated anticoagulation prescription, INR monitoring intensity and time in and outside INR therapeutic range (TTR) stratified by CKD. RESULTS: Of 123 188 patients with newly diagnosed AF, use of warfarin decreased with increasing severity of CKD (57.2%-46.4%), although it was higher among patients on dialysis (62.3%). Although INR monitoring intensity was similar across CKD strata, the proportion with TTR≥60% decreased with CKD severity, with only 21% of patients on dialysis achieving TTR≥60%. After multivariate adjustment, the magnitude of TTR reduction increased with CKD severity. Patients on dialysis had the highest time markedly out of range with INR <1.5 or >3.5 (30%); 12% of INR time was >3.5, and low TTR persisted for up to 3 years. CONCLUSIONS: There is a wide variation in anticoagulation prescription based on CKD severity. Patients with moderate-to-severe CKD, including dialysis, have substantially reduced TTR, despite comparable INR monitoring intensity. These findings have implications for more intensive warfarin management strategies in CKD or alternative therapies such as direct oral anticoagulants. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: Margaret C Fang; Alan S Go; Yuchiao Chang; Leila H Borowsky; Niela K Pomernacki; Natalia Udaltsova; Daniel E Singer Journal: J Am Coll Cardiol Date: 2011-07-19 Impact factor: 24.094
Authors: Sean D Pokorney; DaJuanicia N Simon; Laine Thomas; Gregg C Fonarow; Peter R Kowey; Paul Chang; Daniel E Singer; Jack Ansell; Rosalia G Blanco; Bernard Gersh; Kenneth W Mahaffey; Elaine M Hylek; Alan S Go; Jonathan P Piccini; Eric D Peterson Journal: Am Heart J Date: 2015-04-01 Impact factor: 4.749
Authors: Stuart J Connolly; Janice Pogue; John Eikelboom; Gregory Flaker; Patrick Commerford; Maria Grazia Franzosi; Jeffrey S Healey; Salim Yusuf Journal: Circulation Date: 2008-10-27 Impact factor: 29.690
Authors: N A Mark Estes; Jonathan L Halperin; Hugh Calkins; Michael D Ezekowitz; Paul Gitman; Alan S Go; Robert L McNamara; Joseph V Messer; James L Ritchie; Sam J W Romeo; Albert L Waldo; D George Wyse; Robert O Bonow; Elizabeth DeLong; David C Goff; Kathleen Grady; Lee A Green; Ann Hiniker; Jane Ann Linderbaum; Frederick A Masoudi; Ileana L Piña; Susan Pressler; Martha J Radford; John S Rumsfeld Journal: J Am Coll Cardiol Date: 2008-02-26 Impact factor: 24.094
Authors: Jonathan P Piccini; Susanna R Stevens; YuChiao Chang; Daniel E Singer; Yuliya Lokhnygina; Alan S Go; Manesh R Patel; Kenneth W Mahaffey; Jonathan L Halperin; Günter Breithardt; Graeme J Hankey; Werner Hacke; Richard C Becker; Christopher C Nessel; Keith A A Fox; Robert M Califf Journal: Circulation Date: 2012-12-03 Impact factor: 29.690
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Nisha Bansal; Leila R Zelnick; Kristi Reynolds; Teresa N Harrison; Ming-Sum Lee; Daniel E Singer; Sue Hee Sung; Dongjie Fan; Alan S Go Journal: J Am Soc Nephrol Date: 2021-12-17 Impact factor: 10.121
Authors: Xiaoxi Yao; Jonathan W Inselman; Joseph S Ross; Rima Izem; David J Graham; David B Martin; Aliza M Thompson; Mary Ross Southworth; Konstantinos C Siontis; Che G Ngufor; Karl A Nath; Nihar R Desai; Brahmajee K Nallamothu; Rajiv Saran; Nilay D Shah; Peter A Noseworthy Journal: Circ Cardiovasc Qual Outcomes Date: 2020-10-05